C-Sections & Kids’ Weight; Insulin Pump on the Runway; Hunger With Diet Soda

Babies born via cesarean delivery had significantly higher measures of lean mass, fat mass, and central adiposity compared with those born by vaginal delivery — but this was likely related to the mother’s prepregnancy weight. (JAMA Network Open)

In a pre-specified analysis from the DAPA-CKD trial, dapagliflozin (Farxiga) significantly reduced albuminuria in chronic kidney disease patients both with and without type 2 diabetes, but had differential effects when it came to reducing geometric mean urinary albumin-to-creatinine ratio. (The Lancet Diabetes & Endocrinology)

DreaMed Diabetes AI announced that its Advisor Pro Al Clinical Decision Support System expert-care platform for diabetes has now been FDA cleared for use in both type 1 and type 2 diabetes patients.

MannKind Corporation announced that patient enrollment is officially underway for the company’s INHALE-1 study, testing Technosphere insulin (Afrezza) as an adjunct to basal insulin compared with multiple daily injections in children ages 4 to 17 with either type 1 or type 2 diabetes.

Kate Moss’ 19-year old daughter Lila walked the Milan Fashion Week runway with her Omnipod insulin pump on display. (HuffPost)

Diet sodas — but more specifically the artificial sweetener sucralose in diet beverages — may actually stimulate appetite in females and people with obesity compared with sucrose. (NPR)

Boehringer Ingelheim and Eli Lilly joined forced to launch CRMSynced: a new online game for healthcare professionals to improve cardio-renal-metabolic patient outcomes.

A new analysis from Coherent Market Insights estimated the value of the GLP-1 receptor agonist market to be around $12,720,600 in 2021, and is projecting the market to be valued around $19,253,800 by the year 2028.

  • Kristen Monaco is a staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.